Open AccessAMP ed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy
Author(s) -
Schiewer Matthew J,
Knudsen Karen E
Publication year - 2014
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201303737
Subject(s) - ampk , prostate cancer , medicine , cancer , androgen deprivation therapy , cancer research , androgen receptor , disease , protein kinase a , prostate , amp activated protein kinase , bioinformatics , kinase , biology , microbiology and biotechnology
Despite recent advances in the treatment for metastatic prostatic adenocarcinoma, clinical management of this tumor type remains a major challenge, and there is as of yet no durable cure for advanced disease. Developing pathways that could be co‐targeted alongside the androgen receptor or that would otherwise thwart the development of the CRPC is a current translational and clinical priority. In this issue, a new study by Zadra et al identifies the energy sensor AMPK (5′ AMP‐activated kinase) as a viable therapeutic target in prostate cancer.